IVVD - NASDAQ

Invivyd, Inc.

IVVD·NASDAQ

$1.10

-1.3%

HealthcareBiotechnology

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$146.00M

EPS-0.3000

P/E Ratio-3.67

Earnings Date08/13/2026

ivvd

Research Development Expenses

Last Annual Value

38.31M

3-Year CAGR

-40%

5-Year CAGR

-18%

10-Year CAGR

-10%

Adjust for Inflation

Invivyd, Inc. Competitors Analysis of research-development-expenses

IVVD · NASDAQ

Company	research-development-expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Invivyd, Inc. NASDAQ:IVVD	38.31M	-37.7%	-26.8%	N/A
OmniAb, Inc. NASDAQ:OABI	47.75M	-5.5%	4.0%	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	16.02M	-12.6%	-5.6%	-2.1%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	70.09M	31.0%	14.0%	16.3%
Pyxis Oncology, Inc. NASDAQ:PYXS	73.70M	14.1%	7.6%	N/A
Cassava Sciences, Inc. NASDAQ:SAVA	26.59M	-33.3%	1.4%	11.2%
Vor Biopharma Inc. NASDAQ:VOR	321.53M	50.5%	46.6%	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	112.67M	-21.6%	-13.4%	5.6%
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	3.64M	33.4%	40.1%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	104.24M	-4.0%	1.9%	N/A
Insight Molecular Diagnostics Inc. NASDAQ:IMDX	15.90M	19.6%	25.9%	10.8%

Invivyd, Inc. Fair Value Envelope

IVVD · NASDAQ

Our analysis suggests that IVVD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.1, this represents a potential HIDDEN relative to our calculated worth for Invivyd, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.1

Related Guides

Blog Categories

Continue your IVVD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.